View ValuationAroa Biosurgery 将来の成長Future 基準チェック /46Aroa Biosurgery利益と収益がそれぞれ年間86.8%と13.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.7% 86.4%なると予測されています。主要情報86.8%収益成長率86.41%EPS成長率Biotechs 収益成長39.4%収益成長率13.2%将来の株主資本利益率9.65%アナリストカバレッジLow最終更新日05 May 2026今後の成長に関する最新情報Breakeven Date Change • May 20Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$7.96m in 2027. Average annual earnings growth of 87% is required to achieve expected profit on schedule.Breakeven Date Change • May 01Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$11.5m in 2027. Average annual earnings growth of 99% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 05Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$7.36m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 12Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$8.87m in 2026. Average annual earnings growth of 101% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 23Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$9.26m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.Breakeven Date Change • May 21Forecast breakeven date pushed back to 2026The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 34% to 2025. The company is expected to make a profit of NZ$10.3m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesBreakeven Date Change • May 20Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$7.96m in 2027. Average annual earnings growth of 87% is required to achieve expected profit on schedule.Breakeven Date Change • May 01Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$11.5m in 2027. Average annual earnings growth of 99% is required to achieve expected profit on schedule.お知らせ • Mar 30Aroa Biosurgery Limited Completes Randomised Controlled Trial for SymphonyAroa Biosurgery Limited announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA ECM with high molecular weight hyaluronic acid. The prospective, multi-centre, randomised trial evaluated the safety and performance of Symphony in the treatment of chronic Wagner grade 1 and 2 non-healing diabetic foot ulcers. Patients were randomised to receive either Symphony or standard of care (SOC) dressings on a weekly basis until wound healing or for up to 12 weeks. The study design provided for recruitment of up to 150 patients across multiple sites in the United States. The primary endpoint assessed whether more diabetic foot ulcers healed within the 12-week treatment period with Symphony compared with SOC. Based on the preliminary read-out, the Company believes the trial met its primary endpoint. AROA expects that, once confirmed through final analysis and publication, the results will further support Symphony's clinical efficacy in the management of diabetic foot ulcers. The Company also believes publication of the full study results will help meet the high standard of clinical evidence likely to be required under future reimbursement policies.お知らせ • Feb 17Aroa Biosurgery Limited to Report Fiscal Year 2026 Results on May 31, 2026Aroa Biosurgery Limited announced that they will report fiscal year 2026 results at 10:00 AM, AUS Eastern Standard Time on May 31, 2026お知らせ • Oct 09Aroa Biosurgery Limited to Report Q2, 2026 Results on Oct 16, 2025Aroa Biosurgery Limited announced that they will report Q2, 2026 results Pre-Market on Oct 16, 2025お知らせ • Aug 28Aroa Biosurgery Announces the Findings of the First in Human Study Inviding Its New ENIVO Platform TechnologyAROA announced the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™?) Following Simple Unilateral Mastectomy, which was published in the well-respected journal, Plastic and Reconstructive Surgery, Global Open. The ENIVO platform is designed for the management of 'dead space,' which is an open cavity created by surgical separation or excision of soft tissue. Dead spaces commonly fill with seroma, which can lead to secondary complications, increase the risk of infection, and lengthen hospital stays for patients. AROA's novel ENIVO system is comprised of a wearable vacuum pump connected to a tube and an Aroa ECM sleeve which is implanted within the patient's body. It delivers suction to the surgical site and allows the tissue surfaces at the surgical site to be held closely together, aiming to eliminate the dead space, remove fluid, and improve the speed and quality of healing. The multi-center study, which involved ten patients who had undergone simple unilateral mastectomy where all tissue from one breast is removed, was conducted in New Zealand and led by Associate Professor Michelle B. Locke, MBChB MD. The ENIVO system was used as an alternative to a surgical drain, which is the current standard of care. The shortcomings of drains are well-known - they can fail due to blockages and often lead to seroma formation. Seromas (a collection of fluid that accumulates in a surgical cavity) are one of the most common complications following mastectomy, with reported incidence rates as high as 22-43%. Seromas are associated with delayed wound healing, increased risk of infection and unsatisfactory aesthetic results. The study monitored the patients for a period of three months postoperatively and found that the ENIVO device performed as designed and all patients healed well, with only one clinically relevant seroma recorded. AROA estimates the market opportunity for ENIVO to be in excess of USD 1B, and is actively pursuing commercialisation, with two out of three of the components already having received US FDA clearance. ENIVO is a device in development and is not currently cleared for use in the tested configuration within the United States.お知らせ • Jul 22Aroa Biosurgery Limited to Report Q1, 2026 Results on Jul 29, 2025Aroa Biosurgery Limited announced that they will report Q1, 2026 results at 9:00 AM, E. Australia Standard Time on Jul 29, 2025お知らせ • Jun 27Aroa Biosurgery Limited to Report First Half, 2026 Results on Nov 25, 2025Aroa Biosurgery Limited announced that they will report first half, 2026 results on Nov 25, 2025お知らせ • Jun 25Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025.お知らせ • May 02Aroa Biosurgery Hits Evidence Milestone with Real-World Study Validating the Efficacy of Endoform in Treating Venous Leg UlcersAroa Biosurgery announced a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology. AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing. VLUs are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only 40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur. The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025. The study compared 470 VLUs that had been treated with Endoform Natural to 360 VLUs that had been treatment with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that ' real-world' use of both products could be compared. The study found that VLUs treated with Endoform Natural healed up to 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment. The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural. This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituting collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural. Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72. Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comprehensive effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022;19:7):741-753.お知らせ • Apr 22Aroa Biosurgery Limited to Report Q4, 2025 Results on Apr 29, 2025Aroa Biosurgery Limited announced that they will report Q4, 2025 results Pre-Market on Apr 29, 2025お知らせ • Mar 18+ 1 more updateAroa Biosurgery Limited to Report Fiscal Year 2025 Final Results on Jun 30, 2025Aroa Biosurgery Limited announced that they will report fiscal year 2025 final results at 10:00 AM, AUS Eastern Standard Time on Jun 30, 2025お知らせ • Jan 22Aroa Biosurgery Limited to Report Q3, 2025 Results on Jan 29, 2025Aroa Biosurgery Limited announced that they will report Q3, 2025 results Pre-Market on Jan 29, 2025お知らせ • Oct 15Aroa Biosurgery Limited to Report Q2, 2025 Results on Oct 22, 2024Aroa Biosurgery Limited announced that they will report Q2, 2025 results Pre-Market on Oct 22, 2024Recent Insider Transactions • Oct 06Independent Non-Executive Director recently bought AU$150k worth of stockOn the 30th of September, Catherine Mohr bought around 436k shares on-market at roughly AU$0.34 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$326k more in shares than they have sold in the last 12 months.Breakeven Date Change • Sep 05Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$7.36m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 12Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$8.87m in 2026. Average annual earnings growth of 101% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 23Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$9.26m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.お知らせ • May 26Aroa Biosurgery Limited, Annual General Meeting, Jul 23, 2024Aroa Biosurgery Limited, Annual General Meeting, Jul 23, 2024.Reported Earnings • May 21Full year 2024 earnings released: NZ$0.031 loss per share (vs NZ$0.001 loss in FY 2023)Full year 2024 results: NZ$0.031 loss per share (further deteriorated from NZ$0.001 loss in FY 2023). Revenue: NZ$69.1m (up 9.0% from FY 2023). Net loss: NZ$10.6m (loss widened NZ$10.2m from FY 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Breakeven Date Change • May 21Forecast breakeven date pushed back to 2026The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 34% to 2025. The company is expected to make a profit of NZ$10.3m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.お知らせ • May 15Aroa Biosurgery Limited to Report Fiscal Year 2024 Results on May 21, 2024Aroa Biosurgery Limited announced that they will report fiscal year 2024 results Pre-Market on May 21, 2024Recent Insider Transactions • Feb 24Non-Executive Director recently bought AU$176k worth of stockOn the 16th of February, Philip McCaw bought around 326k shares on-market at roughly AU$0.54 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Breakeven Date Change • Feb 02Forecast to breakeven in 2025The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$2.26m in 2025. Average annual earnings growth of 114% is required to achieve expected profit on schedule.Reported Earnings • Nov 30First half 2024 earnings released: NZ$0.018 loss per share (vs NZ$0.005 profit in 1H 2023)First half 2024 results: NZ$0.018 loss per share (down from NZ$0.005 profit in 1H 2023). Revenue: NZ$31.9m (up 8.6% from 1H 2023). Net loss: NZ$6.31m (down 497% from profit in 1H 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Breakeven Date Change • Nov 29The 4 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of NZ$7.60m in 2025. Average annual earnings growth of 2.3% is required to achieve expected profit on schedule.お知らせ • Nov 29+ 1 more updateAroa Biosurgery Limited Provides Earnings Guidance for the Second Half of the Year 2023Aroa Biosurgery Limited provided earnings guidance for the second half of the year 2023. The company expects revenue of $41 million to $44 million.お知らせ • Jun 30Aroa Biosurgery Limited to Report First Half, 2024 Results on Nov 28, 2023Aroa Biosurgery Limited announced that they will report first half, 2024 results on Nov 28, 2023お知らせ • Jun 07Aroa Biosurgery Limited, Annual General Meeting, Aug 03, 2023Aroa Biosurgery Limited, Annual General Meeting, Aug 03, 2023. Agenda: To consider the election of directors.Breakeven Date Change • Jun 01Forecast breakeven date pushed back to 2025The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NZ$8.04m in 2025. Average annual earnings growth of 83% is required to achieve expected profit on schedule.Reported Earnings • May 31Full year 2023 earnings released: NZ$0.001 loss per share (vs NZ$0.025 loss in FY 2022)Full year 2023 results: NZ$0.001 loss per share (improved from NZ$0.025 loss in FY 2022). Revenue: NZ$63.4m (up 60% from FY 2022). Net loss: NZ$396.0k (loss narrowed 95% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia.お知らせ • May 25Aroa Biosurgery Limited to Report Fiscal Year 2023 Results on May 31, 2023Aroa Biosurgery Limited announced that they will report fiscal year 2023 results Pre-Market on May 31, 2023Breakeven Date Change • May 01Forecast breakeven date moved forward to 2024The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 91% to 2023. The company is expected to make a profit of NZ$18.8k in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule.Breakeven Date Change • Apr 20Forecast breakeven date pushed back to 2025The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 82% per year to 2024. The company is expected to make a profit of NZ$8.68m in 2025. Average annual earnings growth of 89% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 12Forecast breakeven date moved forward to 2024The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 88% to 2023. The company is expected to make a profit of NZ$456.3k in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule.Breakeven Date Change • Feb 10Forecast breakeven date moved forward to 2024The 6 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 80% to 2023. The company is expected to make a profit of NZ$1.02m in 2024. Average annual earnings growth of 150% is required to achieve expected profit on schedule.Board Change • Jan 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Non-Executive Director Catherine Mohr was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Non-Executive Director Catherine Mohr was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.業績と収益の成長予測CHIA:ARX - アナリストの将来予測と過去の財務データ ( )NZD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2029153N/AN/AN/A13/31/202813714161833/31/20271198101333/31/20261044101139/30/202590-236N/A6/30/202588-3-22N/A3/31/202585-4-6-3N/A12/31/202481-6-9-4N/A9/30/202476-8-11-5N/A6/30/202473-9-13-6N/A3/31/202469-11-14-7N/A12/31/202367-9-15-7N/A9/30/202366-8-15-6N/A6/30/202365-4-13-5N/A3/31/2023630-11-4N/A12/31/202257-1-13-7N/A9/30/202251-2-15-10N/A6/30/202245-5-16-11N/A3/31/202240-8-16-12N/A12/31/202135-10-14-10N/A9/30/202131-11-11-8N/A6/30/202127-15-9-6N/A3/31/202122-19-7-5N/A12/31/202022-19-6-5N/A9/30/202021-19-6-4N/A6/30/202023-12-3-1N/A3/31/202025-602N/A3/31/2019241N/A0N/A3/31/201811-1N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ARXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.6% ) よりも高い成長率であると考えられます。収益対市場: ARX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: ARX今後 3 年以内に収益を上げることが予想されます。収益対市場: ARXの収益 ( 13.2% ) Australian市場 ( 6.2% ) よりも速いペースで成長すると予測されています。高い収益成長: ARXの収益 ( 13.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ARXの 自己資本利益率 は、3年後には低くなると予測されています ( 9.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 17:31終値2026/05/22 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aroa Biosurgery Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関John HesterBell PotterElyse ShapiroCanaccord GenuityShane StoreyCanaccord Genuity2 その他のアナリストを表示
Breakeven Date Change • May 20Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$7.96m in 2027. Average annual earnings growth of 87% is required to achieve expected profit on schedule.
Breakeven Date Change • May 01Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$11.5m in 2027. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 05Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$7.36m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 12Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$8.87m in 2026. Average annual earnings growth of 101% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 23Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$9.26m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
Breakeven Date Change • May 21Forecast breakeven date pushed back to 2026The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 34% to 2025. The company is expected to make a profit of NZ$10.3m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
Breakeven Date Change • May 20Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$7.96m in 2027. Average annual earnings growth of 87% is required to achieve expected profit on schedule.
Breakeven Date Change • May 01Forecast breakeven date pushed back to 2027The 3 analysts covering Aroa Biosurgery previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of NZ$11.5m in 2027. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
お知らせ • Mar 30Aroa Biosurgery Limited Completes Randomised Controlled Trial for SymphonyAroa Biosurgery Limited announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial achieved its primary endpoint. Symphony is AROA's Cellular, Acellular and Matrix-like Product (CAMP), or skin substitute, designed for the treatment of hard-to-heal wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers. The product combines multiple layers of AROA ECM with high molecular weight hyaluronic acid. The prospective, multi-centre, randomised trial evaluated the safety and performance of Symphony in the treatment of chronic Wagner grade 1 and 2 non-healing diabetic foot ulcers. Patients were randomised to receive either Symphony or standard of care (SOC) dressings on a weekly basis until wound healing or for up to 12 weeks. The study design provided for recruitment of up to 150 patients across multiple sites in the United States. The primary endpoint assessed whether more diabetic foot ulcers healed within the 12-week treatment period with Symphony compared with SOC. Based on the preliminary read-out, the Company believes the trial met its primary endpoint. AROA expects that, once confirmed through final analysis and publication, the results will further support Symphony's clinical efficacy in the management of diabetic foot ulcers. The Company also believes publication of the full study results will help meet the high standard of clinical evidence likely to be required under future reimbursement policies.
お知らせ • Feb 17Aroa Biosurgery Limited to Report Fiscal Year 2026 Results on May 31, 2026Aroa Biosurgery Limited announced that they will report fiscal year 2026 results at 10:00 AM, AUS Eastern Standard Time on May 31, 2026
お知らせ • Oct 09Aroa Biosurgery Limited to Report Q2, 2026 Results on Oct 16, 2025Aroa Biosurgery Limited announced that they will report Q2, 2026 results Pre-Market on Oct 16, 2025
お知らせ • Aug 28Aroa Biosurgery Announces the Findings of the First in Human Study Inviding Its New ENIVO Platform TechnologyAROA announced the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitled Prospective, First-in-Human Clinical Evaluation of a Novel Tissue Apposition Device (ENIVO™?) Following Simple Unilateral Mastectomy, which was published in the well-respected journal, Plastic and Reconstructive Surgery, Global Open. The ENIVO platform is designed for the management of 'dead space,' which is an open cavity created by surgical separation or excision of soft tissue. Dead spaces commonly fill with seroma, which can lead to secondary complications, increase the risk of infection, and lengthen hospital stays for patients. AROA's novel ENIVO system is comprised of a wearable vacuum pump connected to a tube and an Aroa ECM sleeve which is implanted within the patient's body. It delivers suction to the surgical site and allows the tissue surfaces at the surgical site to be held closely together, aiming to eliminate the dead space, remove fluid, and improve the speed and quality of healing. The multi-center study, which involved ten patients who had undergone simple unilateral mastectomy where all tissue from one breast is removed, was conducted in New Zealand and led by Associate Professor Michelle B. Locke, MBChB MD. The ENIVO system was used as an alternative to a surgical drain, which is the current standard of care. The shortcomings of drains are well-known - they can fail due to blockages and often lead to seroma formation. Seromas (a collection of fluid that accumulates in a surgical cavity) are one of the most common complications following mastectomy, with reported incidence rates as high as 22-43%. Seromas are associated with delayed wound healing, increased risk of infection and unsatisfactory aesthetic results. The study monitored the patients for a period of three months postoperatively and found that the ENIVO device performed as designed and all patients healed well, with only one clinically relevant seroma recorded. AROA estimates the market opportunity for ENIVO to be in excess of USD 1B, and is actively pursuing commercialisation, with two out of three of the components already having received US FDA clearance. ENIVO is a device in development and is not currently cleared for use in the tested configuration within the United States.
お知らせ • Jul 22Aroa Biosurgery Limited to Report Q1, 2026 Results on Jul 29, 2025Aroa Biosurgery Limited announced that they will report Q1, 2026 results at 9:00 AM, E. Australia Standard Time on Jul 29, 2025
お知らせ • Jun 27Aroa Biosurgery Limited to Report First Half, 2026 Results on Nov 25, 2025Aroa Biosurgery Limited announced that they will report first half, 2026 results on Nov 25, 2025
お知らせ • Jun 25Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025Aroa Biosurgery Limited, Annual General Meeting, Aug 20, 2025.
お知らせ • May 02Aroa Biosurgery Hits Evidence Milestone with Real-World Study Validating the Efficacy of Endoform in Treating Venous Leg UlcersAroa Biosurgery announced a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology. AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing. VLUs are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only 40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur. The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025. The study compared 470 VLUs that had been treated with Endoform Natural to 360 VLUs that had been treatment with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that ' real-world' use of both products could be compared. The study found that VLUs treated with Endoform Natural healed up to 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment. The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural. This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituting collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural. Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72. Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comprehensive effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022;19:7):741-753.
お知らせ • Apr 22Aroa Biosurgery Limited to Report Q4, 2025 Results on Apr 29, 2025Aroa Biosurgery Limited announced that they will report Q4, 2025 results Pre-Market on Apr 29, 2025
お知らせ • Mar 18+ 1 more updateAroa Biosurgery Limited to Report Fiscal Year 2025 Final Results on Jun 30, 2025Aroa Biosurgery Limited announced that they will report fiscal year 2025 final results at 10:00 AM, AUS Eastern Standard Time on Jun 30, 2025
お知らせ • Jan 22Aroa Biosurgery Limited to Report Q3, 2025 Results on Jan 29, 2025Aroa Biosurgery Limited announced that they will report Q3, 2025 results Pre-Market on Jan 29, 2025
お知らせ • Oct 15Aroa Biosurgery Limited to Report Q2, 2025 Results on Oct 22, 2024Aroa Biosurgery Limited announced that they will report Q2, 2025 results Pre-Market on Oct 22, 2024
Recent Insider Transactions • Oct 06Independent Non-Executive Director recently bought AU$150k worth of stockOn the 30th of September, Catherine Mohr bought around 436k shares on-market at roughly AU$0.34 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$326k more in shares than they have sold in the last 12 months.
Breakeven Date Change • Sep 05Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$7.36m in 2026. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 12Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$8.87m in 2026. Average annual earnings growth of 101% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 23Forecast to breakeven in 2026The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$9.26m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
お知らせ • May 26Aroa Biosurgery Limited, Annual General Meeting, Jul 23, 2024Aroa Biosurgery Limited, Annual General Meeting, Jul 23, 2024.
Reported Earnings • May 21Full year 2024 earnings released: NZ$0.031 loss per share (vs NZ$0.001 loss in FY 2023)Full year 2024 results: NZ$0.031 loss per share (further deteriorated from NZ$0.001 loss in FY 2023). Revenue: NZ$69.1m (up 9.0% from FY 2023). Net loss: NZ$10.6m (loss widened NZ$10.2m from FY 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Breakeven Date Change • May 21Forecast breakeven date pushed back to 2026The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 34% to 2025. The company is expected to make a profit of NZ$10.3m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule.
お知らせ • May 15Aroa Biosurgery Limited to Report Fiscal Year 2024 Results on May 21, 2024Aroa Biosurgery Limited announced that they will report fiscal year 2024 results Pre-Market on May 21, 2024
Recent Insider Transactions • Feb 24Non-Executive Director recently bought AU$176k worth of stockOn the 16th of February, Philip McCaw bought around 326k shares on-market at roughly AU$0.54 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Breakeven Date Change • Feb 02Forecast to breakeven in 2025The 5 analysts covering Aroa Biosurgery expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$2.26m in 2025. Average annual earnings growth of 114% is required to achieve expected profit on schedule.
Reported Earnings • Nov 30First half 2024 earnings released: NZ$0.018 loss per share (vs NZ$0.005 profit in 1H 2023)First half 2024 results: NZ$0.018 loss per share (down from NZ$0.005 profit in 1H 2023). Revenue: NZ$31.9m (up 8.6% from 1H 2023). Net loss: NZ$6.31m (down 497% from profit in 1H 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Nov 29The 4 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of NZ$7.60m in 2025. Average annual earnings growth of 2.3% is required to achieve expected profit on schedule.
お知らせ • Nov 29+ 1 more updateAroa Biosurgery Limited Provides Earnings Guidance for the Second Half of the Year 2023Aroa Biosurgery Limited provided earnings guidance for the second half of the year 2023. The company expects revenue of $41 million to $44 million.
お知らせ • Jun 30Aroa Biosurgery Limited to Report First Half, 2024 Results on Nov 28, 2023Aroa Biosurgery Limited announced that they will report first half, 2024 results on Nov 28, 2023
お知らせ • Jun 07Aroa Biosurgery Limited, Annual General Meeting, Aug 03, 2023Aroa Biosurgery Limited, Annual General Meeting, Aug 03, 2023. Agenda: To consider the election of directors.
Breakeven Date Change • Jun 01Forecast breakeven date pushed back to 2025The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NZ$8.04m in 2025. Average annual earnings growth of 83% is required to achieve expected profit on schedule.
Reported Earnings • May 31Full year 2023 earnings released: NZ$0.001 loss per share (vs NZ$0.025 loss in FY 2022)Full year 2023 results: NZ$0.001 loss per share (improved from NZ$0.025 loss in FY 2022). Revenue: NZ$63.4m (up 60% from FY 2022). Net loss: NZ$396.0k (loss narrowed 95% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia.
お知らせ • May 25Aroa Biosurgery Limited to Report Fiscal Year 2023 Results on May 31, 2023Aroa Biosurgery Limited announced that they will report fiscal year 2023 results Pre-Market on May 31, 2023
Breakeven Date Change • May 01Forecast breakeven date moved forward to 2024The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 91% to 2023. The company is expected to make a profit of NZ$18.8k in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule.
Breakeven Date Change • Apr 20Forecast breakeven date pushed back to 2025The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 82% per year to 2024. The company is expected to make a profit of NZ$8.68m in 2025. Average annual earnings growth of 89% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 12Forecast breakeven date moved forward to 2024The 5 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 88% to 2023. The company is expected to make a profit of NZ$456.3k in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule.
Breakeven Date Change • Feb 10Forecast breakeven date moved forward to 2024The 6 analysts covering Aroa Biosurgery previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 80% to 2023. The company is expected to make a profit of NZ$1.02m in 2024. Average annual earnings growth of 150% is required to achieve expected profit on schedule.
Board Change • Jan 05Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Non-Executive Director Catherine Mohr was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 17Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Non-Executive Director Catherine Mohr was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.